Clinical Research Office. A partnership between Sheffield Teaching Hospitals NHS Foundation Trust and the University of Sheffield

Academic Directorate of Specialised Medicine: Dermatology

Key Contacts

Name Role
Prof Mike Cork
Research Lead
Josh Wright
Clinical Director
Dr Ruth Sabroe 
Clinical Lead
Ian Scott
Operations Director
Kath Knight
Deputy Operations Director
Julie Senior
Deputy Group Finance Manager
Mark Palmer
Directorate Accountant
Sarah Moll
Directorate Research Coordinator 
Gaurika Kapoor
Clinical Research Office Coordinator
(Industry-Sponsored Studies)

Dermatology Research.

(Research Lead on Specialised Medicine Executive – Prof Andrew Messenger)

The majority of substantive STH consultants are active PIs in research studies and this is supported by the specialty registrars.  There is also a 0.6 FT Research Nurse funded by the RCF.  Research is promoted through the Dermatology local specialty group (LSG) which meets three times a year and discusses the research process and current and future projects. There is significant and increasing interaction with clinicians and research nurses beyond Sheffield with the aim of fostering involvement of DGH departments in portfolio research projects.  Given the merger of the three Yorkshire LSGs that occurred in April 2014, it is envisaged that a rotating programme of meetings through the three sub-regions will be established, e.g. one meeting in each sub-region per year as well as maintaining a local program. 

Research capacity may be increased with the recent appointment of 1.6 WTE new consultants who will take up their posts in April 2015.

Portfolio studies:

Non-commercial -
  • Genetics of Acne – this study has recruited very well and we have comfortably exceeded our target. The project has been extended to October 2014 and we therefore have the opportunity to continue recruitment providing research nurse support is available.
  • Aetiology of frontal fibrosing alopecia – this study has also recruited to target and has now closed. The results are being analysed and some interesting and potentially important associations are emerging. We aim to submit a preliminary report of the work to the forthcoming World Congress for Hair Research (May 2014).
  • BADBIR – we will continue to recruit to this study. Our target has been amended and should be achievable. 
  • B-STOP ­– the inclusion criteria for this study have been tightened up. Recruitment has been rather slow but there is a good chance we will achieve our target.
  • Treatment of vitiligo – this study has been hampered by an unforeseen and unavoidable reduction in nursing support but is making reasonable progress nevertheless.

Commercial -

  • Eli-Lilly – new biologic (LY2439821) vs etanercept in the treatment of psoriasis – for a number of reasons we struggled to recruit to this commercial study and only managed two recruits. This study has now closed.
  • OC000459 in the treatment of atopic dermatitis (STH18010) – recruitment to this study has recently commenced.

Forthcoming studies:

  • L’Oreal hair dye study (STH16486) – this study is still being developed but we hope it will commence later this year. The protocol is quite intensive but we have a substantial patient resource on which to draw.